---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-159898"
form_type: "8-K"
ticker: "SGHT"
cik: "0001531177"
company_name: "Sight Sciences, Inc."
filed_at: "2023-06-02T23:59:59+00:00"
generated_at: "2026-06-14T08:10:46.303624+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Sight Sciences reaffirms FY23 revenue guidance; WPS proposes limiting MIGS coverage for OMNI

## Summary
- Reaffirmed FY2023 revenue guidance of $89M-$94M (25%-32% growth YoY); quarterly adjusted opex ~$30.5M.
- WPS (Medicare contractor) proposed LCD classifying non-implantable MIGS as investigational; would make OMNI non-covered in 6 states.
- WPS-served states (KS, NE, MO, IA, IN, MI) accounted for ~8% of Surgical Glaucoma revenue in 2022.
- Company strongly disagrees, plans to present clinical evidence at WPS meeting June 14 and comment period through July 15.
- Precedent: Palmetto GBA withdrew similar 2020 LCD after ophthalmic community pushback.

## SEC filing metadata
- accession: 0001193125-23-159898
- form_type: 8-K
- ticker: SGHT
- cik: 0001531177
- company_name: Sight Sciences, Inc.
- filed_at: 2023-06-02T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1531177/000119312523159898/0001193125-23-159898-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1531177/000119312523159898/d515447d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-159898
- JSON: https://secwatch.observer/filing/0001193125-23-159898.json
- Plain text: https://secwatch.observer/filing/0001193125-23-159898.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.